Voglinorm GM1/0.3

Voglinorm Gm1/0.3 contains Glimepiride 1 mg + Voglibose 0.3 mg (tablet). Prescription required.

Type 2 diabetes mellitus; used to improve blood sugar control in adults when diet and exercise alone or single therapy is inadequate.

Glimepiride (a sulfonylurea) increases insulin release from the pancreas and improves peripheral glucose utilization. Voglibose (an alpha‑glucosidase inhibitor) delays intestinal carbohydrate digestion and absorption, reducing post‑meal blood glucose spikes.

Take orally as prescribed. Usually taken once daily just before or with the first main meal; swallow whole with water. Do not skip meals after taking; follow diet/exercise plan and monitor blood glucose.

Hypoglycaemia, dizziness, headache, nausea, abdominal pain, flatulence, diarrhoea, bloating, weight gain

Risk of hypoglycaemia (higher with missed meals, alcohol, excessive exercise, elderly, renal/hepatic impairment); monitor blood glucose regularly. Use with caution in kidney or liver disease. Not recommended in type 1 diabetes or diabetic ketoacidosis. If severe abdominal pain or persistent GI symptoms occur, seek medical advice. Inform doctor before surgery/acute illness as dose adjustment may be needed.

Alcohol (increases hypoglycaemia risk), insulin/other antidiabetics (additive hypoglycaemia), beta-blockers (mask hypoglycaemia symptoms), corticosteroids/thyroid hormones/diuretics (may raise glucose), fluoroquinolones (glucose disturbances), azole antifungals and macrolides (may increase glimepiride effect), rifampicin (may reduce glimepiride effect)

Store below 25°C in a cool, dry place away from moisture and direct light. Keep out of reach of children.

Glimepiride 1 mg + Voglibose 0.3 mg tablets (various brands), Vogli-GM 1/0.3 Tablet, Voglibose+Glimepiride 1/0.3 Tablet (generic equivalents), Glycomet-GP 1/0.3 (brand variants), Glimy-V 1/0.3 (brand variants)